Midcap Pharma Company Marksans Pharma Hits 52-Week High, Outperforms Sector

Marksans Pharma, a midcap pharmaceutical company, has recently seen a surge in its stock price, reaching a 52-week high on July 11, 2024. The stock has been performing well in the market, with a 'Hold' call from MarketsMOJO. On July 11, the stock hit a new 52-week and all-time high of Rs.197.15, outperforming the sector by 2.91%. It has also shown consecutive gains for the last 2 days, with a 3.4% increase in returns during this period. The stock's intraday high was Rs.197.15, a 4.87% increase. Marksans Pharma is currently trading above its 5-day, 20-day, 50-day, 100-day, and 200-day moving averages, indicating a positive trend in the market. In the past year, Marksans Pharma has shown a remarkable performance of 107.15%, while the Sensex has only seen a 21.86% increase. This showcases the company's strong growth and potential in the pharmaceutical industry. As a midcap company, Marksans Pharma has established itself as a key player in the market, with a promising future ahead. With its recent stock price surge and positive performance, it is definitely a company to keep an eye on in the pharma industry.